Cytokinetics Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while iShares 7-10 Year Treasury Bond ETF trades at $93.66. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | IEF | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $97.99 |
52-Week Low | $33.23 | $93.11 |
Enterprise Value | $11.59B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
IEF trades at $93.29, down 0.36% on the day, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators but oversold short-term RSI. Recent news highlights bond ETF inflows and investor focus on yield amid Federal Reserve uncertainty, with articles from Benzinga (July 14, 2026) and CNBC (June 25, 2026) noting record flows and rate hike speculation.
Outlook remains cautious due to interest rate sensitivity and macroeconomic pressures. Risks include potential Fed hikes and inflation concerns, but the oversold RSI may offer short-term support. Investors should weigh yield attractiveness against duration risk in the current rate environment.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →